Physician profile
Ellen Ferguson
NPI 1770541518
$3,545.64
in general payments reported to CMS, 2019-2025
34 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $216 · 2021: $573 · 2022: $467 · 2023: $536 · 2024: $766 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $426.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $411.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $319.15 | 2019-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $290.17 | 2019-2025 | Veozah |
| Abbvie INC. | $276.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $220.85 | 2021-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $219.95 | 2019-2025 | Airsupra, Farxiga |
| Inspire Medical Systems, INC. | $211.28 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $138.62 | 2021-2024 | |
| Pfizer INC. | $98.30 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $88.89 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $79.38 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $79.10 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $70.47 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $65.18 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.07 | 2024-2025 | Dexcom G6 Transmitter |
| Emmaus Medical, INC. | $44.09 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $41.26 | 2022 | |
| Boston Scientific Corporation | $40.61 | 2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.85 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.92 | 2021-2024 | Xifaxan, Trulance |
| Almatica Pharma LLC | $32.36 | 2021 | |
| Allergan, INC. | $29.99 | 2020 | |
| Linus Health, INC. | $27.88 | 2022-2024 | Core Cognitive Evaluation |
| Seqirus USA INC | $25.31 | 2025 | Flucelvax, Fluad |
| Amarin Pharma, INC. | $24.90 | 2019 | |
| Welch Allyn | $22.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.22 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.15 | 2024 | Voquezna |
| Echosens North America, INC. | $16.22 | 2024 | Fibroscan |
| Amneal Pharmaceuticals LLC | $15.98 | 2023 | Unithroid |
| Abbott Laboratories | $15.44 | 2021 | |
| Sanofi Pasteur INC. | $15.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.